Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EQL Pharma AB ( (SE:EQL) ) has issued an update.
EQL Pharma AB faced a challenging second quarter in 2025 due to unforeseen delivery disruptions, resulting in a mere 1% sales growth and a significant drop in operating profit. Despite these setbacks, the company remains optimistic about achieving its long-term growth targets, with strategic initiatives to improve supply chain transparency and efficiency. The company is also expanding its geographic reach, with the launch of Mellozzan in the UK and marketing approval in Turkey, aiming for significant sales growth in the German and Dutch markets.
More about EQL Pharma AB
EQL Pharma AB operates in the pharmaceutical industry, focusing on developing and marketing niche generic drugs. The company aims to expand its market presence in Germany and the Netherlands, with a strategic focus on building a robust generic portfolio.
Average Trading Volume: 49,923
Technical Sentiment Signal: Hold
Current Market Cap: SEK1.83B
Learn more about EQL stock on TipRanks’ Stock Analysis page.